
To evaluate the efficacy of zzso zzso 200 zzso zzso every 2 weeks after therapeutic substitution for zzso zzso 

zzso zzso chart zzso 

Three US zzso zzso zzso 

Three hundred thirty anemic patients with zzso zzso of whom 174 had been treated previously with zzso zzso zzso zzso and 156 had not been treated recently with zzso zzso zzso zzso 

zzso substitution with zzso zzso was started according to the US Oncology Pharmacy and zzso Committee's recommended dosing zzso anemic patients with cancer received a starting dosage of zzso zzso 200 zzso every 2 weeks regardless of whether or not they had previously received zzso zzso Hematologic and zzso zzso usage data were zzso from consecutive medical records dated from May zzso zzso 

Median exposure to zzso zzso was 10 weeks zzso zzso 6 zzso 75th zzso 17 zzso and 10 weeks zzso zzso 5 zzso 75th zzso 18 zzso for the zzso and switched groups, zzso The week before the switch to zzso zzso the 174 patients receiving zzso zzso were administered the following weekly zzso less than 40,000 U zzso 40,000 U zzso or zzso U zzso Mean zzso level increased from baseline zzso zzso in both the zzso and switched zzso The proportion of patients receiving a red blood cell zzso in the zzso zzso treatment phase was low zzso in each zzso No variation in zzso rates was observed across weight categories in patients who received a fixed dosage of zzso zzso zzso zzso was well zzso A detailed usage zzso was validated by these results and is being used in these three US zzso zzso 

A zzso zzso starting dosage of 200 zzso zzso every 2 weeks administered according to US zzso dosing guidelines is effective in treating zzso anemia in both zzso zzso patients and those switched from zzso zzso 

